Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
103 hedge funds and large institutions have $730M invested in Blueprint Medicines in 2016 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 43 increasing their positions, 20 reducing their positions, and 11 closing their positions.
155% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 11
115% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 20
80.56% more ownership
Funds ownership: 0% → 80.56% (+81%)
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
29% more capital invested
Capital invested by funds: $567M → $730M (+$163M)
18% more funds holding
Funds holding: 87 → 103 (+16)
58% less call options, than puts
Call options by funds: $378K | Put options by funds: $896K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$49M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$24.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$16.4M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$14.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$11.2M |
| 2 |
PA
Perceptive Advisors
New York
|
-$5.61M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$4.68M |
| 4 |
SIM
Spark Investment Management
New York
|
-$2.57M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.55M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Creative Planning
Overland Park,
Kansas
| $3K | – | – | – |
|
|
HMS
102
Hanseatic Management Services
Albuquerque,
New Mexico
| $1K | +$573 | +19 | New |
|
103
US Bancorp
Minneapolis,
Minnesota
| $1K | +$1.42K | +47 | New |
|
|
RG
104
Redmile Group
San Francisco,
California
| – | -$818K | -27,539 | Closed |
|
105
Millennium Management
New York
| – | -$653K | -22,003 | Closed |
|
|
DC
106
Deere & Company
Moline,
Illinois
| – | -$476K | -16,023 | Closed |
|
|
OAM
107
Oxford Asset Management
Oxford,
United Kingdom
| – | -$345K | -11,620 | Closed |
|
108
UBS AM
Chicago,
Illinois
| – | -$327K | -11,015 | Closed |
|
109
Two Sigma Investments
New York
| – | -$288K | -9,700 | Closed |
|
|
GAM
110
Gotham Asset Management
New York
| – | -$257K | -8,656 | Closed |
|
|
FIM
111
Fernwood Investment Management
Quincy,
Massachusetts
| – | -$208K | -7,000 | Closed |
|
|
ACH
112
ArrowMark Colorado Holdings
Denver,
Colorado
| – | -$116K | -3,900 | Closed |
|
|
PAM
113
Panagora Asset Management
Boston,
Massachusetts
| – | -$44K | -1,486 | Closed |
|
114
Simplex Trading
Chicago,
Illinois
| – | -$11.2K | -370 | Closed |
|
BPMC Hedge Fund Activity: Q4 2016 in Review
103 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q4 2016, worth a combined $730M — up 29% from $567M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new BPMC positions and 11 closed out — a net gain of 17 holders — while 43 added to existing stakes and 20 trimmed.
The largest buyer was Deerfield Management, adding an estimated $49M. The largest seller was Fidelity International, cutting an estimated $11.2M.
- 103 institutional investors held Blueprint Medicines (BPMC) as of Q4 2016, up from 87 in Q3 2016.
- Funds reported $730M of Blueprint Medicines stock for Q4 2016, up 29% quarter-over-quarter.
- 28 funds opened new Blueprint Medicines positions in Q4 2016 and 11 closed out, a net change of +17 holders.
- The largest Blueprint Medicines buyer in Q4 2016 was Deerfield Management, an estimated $49M added.
- The largest Blueprint Medicines seller in Q4 2016 was Fidelity International, an estimated $11.2M sold.
Based on aggregated 13F filings for Q4 2016.